RT Journal Article
SR Electronic
T1 Evaluating the Perceived Utility of an Artificial Intelligence-Powered Clinical Decision Support System for Depression Treatment Using a Simulation Centre
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.21.21255899
DO 10.1101/2021.04.21.21255899
A1 Myriam Tanguay-Sela
A1 David Benrimoh
A1 Christina Popescu
A1 Tamara Perez
A1 Colleen Rollins
A1 Emily Snook
A1 Eryn Lundrigan
A1 Caitrin Armstrong
A1 Kelly Perlman
A1 Robert Fratila
A1 Joseph Mehltretter
A1 Sonia Israel
A1 Monique Champagne
A1 Jérôme Williams
A1 Jade Simard
A1 Sagar V. Parikh
A1 Jordan F. Karp
A1 Katherine Heller
A1 Outi Linnaranta
A1 Liliana Gomez Cardona
A1 Gustavo Turecki
A1 Howard Margolese
YR 2021
UL http://medrxiv.org/content/early/2021/04/25/2021.04.21.21255899.abstract
AB Aifred is a clinical decision support system (CDSS) that uses artificial intelligence to assist physicians in selecting treatments for major depressive disorder (MDD) by providing probabilities of remission for different treatment options based on patient characteristics. We evaluated the utility of the CDSS as perceived by physicians participating in simulated clinical interactions. Twenty psychiatry and family medicine staff and residents completed a study in which each physician had three 10-minute clinical interactions with standardized patients portraying mild, moderate, and severe episodes of MDD. During these scenarios, physicians were given access to the CDSS, which they could use in their treatment decisions. The perceived utility of the CDSS was assessed through self-report questionnaires, scenario observations, and interviews. 60% of physicians perceived the CDSS to be a useful tool in their treatment-selection process, with family physicians perceiving the greatest utility. Moreover, 50% of physicians would use the tool for all patients with depression, with an additional 35% noting they would reserve the tool for more severe or treatment-resistant patients. Furthermore, clinicians found the tool to be useful in discussing treatment options with patients. The efficacy of this CDSS and its potential to improve treatment outcomes must be further evaluated in clinical trials.Competing Interest StatementD.B., C.A., R.F., S.I., K.P. are shareholders and either employees, directors, or founders of Aifred Health. M.T.S. is employed by Aifred Health and is an options holder. C.P., K.F.H., G.S., E.L., J.B., T.P., D.S., B.D. have been or are employed or financially compensated by Aifred Health. S.P., K.H., J.K. are members of Aifred Health's scientific advisory board and have received payments or options. H.M. has received honoraria, sponsorship or grants for participation in speaker bureaus, consultation, advisory board meetings and clinical research from Acadia, Amgen, HLS Therapeutics, Janssen-Ortho, Mylan, Otsuka-Lundbeck, Perdue, Pfizer, Shire and SyneuRx International. All other authors report no relevant conflicts.Funding StatementFunding sources: Aifred Health Inc.; Innovation Research Assistance Program, National Research Council Canada; ERA-Permed Vision 2020 supporting IMADAPT; Government of Quebec Nova Science; MEDTEQ COVID-Relief Grant. Use of the simulation centre and the work of the standardised patients was provided as part of the prize for a clinical innovation competition run by McGill University and the Steinberg Centre for Simulation and Interactive Learning, Canada, with the generous support of the Hakim family.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Douglas Mental Health University Institute Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publicly available. Interested parties should contact the authors.